PTS Diagnostics Announces New Retail Point-of-Care Software
PTS Connect ProLink ® platform expands connectivity and informatics offerings
INDIANAPOLIS, Jan. 04, 2018 (GLOBE NEWSWIRE) -- PTS Diagnostics, a U.S.-based manufacturer of point-of-care biometric testing devices, today announced that they are releasing PTS Connect ProLink, a cloud-based biometric data collection and transfer software platform that helps retail partners' pharmacies and clinics provide valuable health screening services to their customers.
Unlike other data capture systems, PTS Connect ProLink delivers a personalized wellness report through wireless technology. The solution seamlessly and instantly transfers test results from PTS Diagnostic's CardioChek® PA and CardioChek Plus analyzers to a secure online portal.
"Basic health and wellness data is most effective when delivered to the patient as part of a face-to-face consultation," said Robert Huffstodt, President and CEO of PTS Diagnostics. "This new connectivity platform combined with our proven point-of-care solutions allows us to better serve both the healthcare provider and those impacted by chronic diseases."
The software, developed by Cystelcom Sistemas, S.A., is powered by the company's mHealthAlert software. It combines original hardware with intuitive software that wirelessly receives and securely stores biometric data from various diagnostics devices. All this can be done using any modern iOS, Android or Windows computer as well as mobile phones and tablets.
"The mHealthAlert software, developed specifically for retail pharmacies and clinics, is the engine that drives PTS Connect ProLink," said Manuel Cuenca, CEO of Cystelcom Sistemas, S.A. "We're proud to partner with a forward-thinking company such as PTS Diagnostics. Together, we will craft a niche in the ever-growing field of population health management."
As pharmacy-based retail clinics continue to become key players in today's healthcare market, many are looking to stay ahead of the curve by offering critical health screening services in-store. PTS Connect ProLink provides a solution designed with retail screeners in mind, offering benefits such as:
- Increased traffic by offering quick, convenient, wellness screening services
- Personalized, printable wellness reports including company logo
- HIPAA-compliant data on the health needs of customers
PTS Connect ProLink is available in the United States and abroad. To learn more, reach out to a PTS Diagnostics' area sales manager, email CustomerService@ptsdiagnostics.com, or call 877-870-5610 (toll-free in the U.S.).
About PTS Diagnostics:
Through its People, Technology and Service, PTS Diagnostics creates health innovation that drives action and results. Since 1992, we have helped medical professionals and patients achieve better health outcomes through our accurate, precise, fast, affordable, and certified point-of-care medical devices. Healthcare professionals have used our CardioChek products to assess cardiovascular disease risks for more than 140 million patients worldwide through lipid panel screening. And, our A1CNow® systems, which provide fast and reliable HbA1c testing, have helped physicians deliver more effective treatments to patients with diabetes. From our headquarters in the United States of America, we design, manufacture, and market our products to more than 140 countries around the globe. For more information, visit ptsdiagnostics.com .
About Cystelcom Sistemas, S.A:
Cystelcom has been focused on providing software solutions since 1993. The company's interest in healthcare began when Cystelcom's founder, Mr. Manuel Cuenca, identified the need to share biometric data from his father who was ill to his father's doctors. As a consequence, mHealthAlert was developed using Artificial Intelligence algorithms to help track patients with various illnesses and a fully functioning portal focused on patient wellness. Cystelcom has teamed with large companies such as Cisco, SAP, Vodafone, Fujitsu, and many hospitals in the EU. Headquartered in Madrid, Spain, Cystelcom continues to grow and serve its markets with a keen eye on the patient's health.
Ryan Simpson, Marketing Associate
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PTS Diagnostics via Globenewswire
Följ NASDAQ OMX
Abonnera på våra pressmeddelanden.
Senaste pressmeddelandena från NASDAQ OMX
Canada's CoinField cryptocurrency exchange going international with commission-free trading app moonGO through a new partnership23.7.2018 11:30 | Pressmeddelande
moonGO(TM) app is the fastest and most reliable way to buy/sell and store cryptocurrencies. The app allows users to convert cryptos directly to EUR/USD to be loaded into their moonGo(TM) card and be used anywhere worldwide whether they're shopping online or spending it at a physical retailer who accepts credit cards. VANCOUVER, British Columbia, July 23, 2018 (GLOBE NEWSWIRE) -- CoinField, the most advanced cryptocurrency exchange in Canada is now extending its services worldwide thanks to a new partnership with Malta's Manticore Ventures to create moonGO(TM), a powerful app designed for traders who thrive on agility, flexibility and security. With moonGO(TM), users can set up their trading accounts in about 60 seconds, withdraw fiat currency as Euro or US dollars in the form of moonGO(TM) cards, and use the moonGO(TM) cards to make purchases online or at any retailer that accepts credit cards. The moonGO(TM) app will take CoinField's sterling reputation outside of Canada and make its
UK drafts new M. genitalium guidelines: Resistance Guided Therapy to tackle antibiotic resistance23.7.2018 09:00 | Pressmeddelande
BASHH aiming to raise awareness of Mgen and curb rising antibiotic resistance LONDON, July 23, 2018 (GLOBE NEWSWIRE) -- The British Association of Sexual Health and HIV (BASHH) draft guidelines for the sexually transmitted infection Mycoplasma genitalium (Mgen) were posted for consultation on July 8th, 20181[link]. The guideline recommends Resistance Guided Therapy as best practice when treating an Mgen infection, with a strong recommendation for diagnostic tests to direct appropriate antibiotic treatment. Mgen is highly resistant to antibiotics, up to 50% of infections are already resistant to the first-line treatment, azithromycin.2,3 This rate may rise if infections are treated without knowledge of resistance status. The success of Resistance Guided Therapy as treatment for Mgen was published in Clinical Infectious Diseases, June 20182 [link].Cure rates increased from under 68% to over 92% by switching the first-line drug and using the SpeeDx Resistance Plus® MG* test to triage pati
LeoVegas AB: Inbjudan till presentation av LeoVegas delårsrapport för andra kvartalet 201823.7.2018 08:00 | Pressmeddelande
LeoVegas delårsrapport för det andra kvartalet för 2018 kommer att publiceras klockan 08:00 den 1:a augusti 2018. En webbsänd telefonkonferens kommer att hållas klockan 09:00 samma dag där Gustaf Hagman, VD och medgrundare samt Viktor Fritzén, CFO, presenterar resultatet. Det kommer att finnas möjlighet att ställa frågor via webbsändningen där även presentationsmaterialet går att följa. Webbsändningen nås på adressen: https://edge.media-server.com/m6/p/zupwii5n För att delta i telefonkonferensen via telefon, vänligen ring in på något av följande nummer: SE: +46 (0) 8 5664 2753 UK: +44 (0) 330 336 9128 US: +1 646 828 8144 Bekräftelse kod: 5362090 Webbsändningen, som även kan ses i efterhand, och presentationsmaterialet kommer att finnas tillgängligt på LeoVegas webbplats www.leovegasgroup.com under Investor Relations. För ytterligare information, vänligen kontakta: Gustaf Hagman, Group CEO och medgrundare: +46 (0) 8 410 367 66, firstname.lastname@example.org Philip Doftvik, Head of Investor
LeoVegas AB: Invitation to presentation of LeoVegas second quarter 201823.7.2018 08:00 | Pressmeddelande
LeoVegas interim report for the second quarter for 2018 will be published at 08:00 CET on August 1, 2018. A webcast telephone conference will be held at 09:00 CET the same day, where Gustaf Hagman, CEO and Co-founder, and Viktor Fritzén, CFO, will present the results. A possibility will be given to ask questions via the webcast and follow the presentation live. The webcast will be accessible at: https://edge.media-server.com/m6/p/zupwii5n To participate in the conference call by phone, please call one of the following numbers: SE: +46 (0) 8 5664 2753 UK: +44 (0) 330 336 9128 US: +1 646 828 8144 Confirmation code: 5362090 The webcast, which afterwards also will be available on demand, and presentation material will be published on LeoVegas website, www.leovegasgroup.com under Investor Relations. For further information, please contact: Gustaf Hagman, Group CEO: +46 (0) 8 410 367 66, email@example.com Philip Doftvik, Head of Investor Relations and corporate finance: +46 73 512 0
Gratomic Announces Non-Brokered Private Placement21.7.2018 19:41 | Pressmeddelande
TORONTO, July 21, 2018 (GLOBE NEWSWIRE) -- Gratomic Inc. ("GRAT" or the "Company") (TSX-V:GRAT) (FRANKFURT:CB81) (WKN:A143MR) is pleased to announce the offering of a non-brokered private placement of up to 20,000,000 working capital units (the "WC Unit") for up to $2,000,000 (the "Offering"). Each WC Unit is priced at $0.10 and consists of one (1) common share and one (1) common share purchase warrant ("WC Warrant"). Each WC Warrant entitles the holder to purchase one (1) common share (a "WC Warrant Share") at a price of $0.20 per WC Warrant Share until the earlier of: (i) three (3) years following the Closing of the Offering; and (ii) in the event that the closing price of the Common Shares on the TSX Venture Exchange is at least $0.30 for ten (10) consecutive trading days, and the 10th trading day (the "Final Trading Day") is at least four (4) months from the Closing Date, the date which is thirty (30) days from the Final Trading Day. Eligible Finders may receive 5% of the value of
eGain Enables Conversational Customer Service Through Apple Business Chat20.7.2018 12:30 | Pressmeddelande
SUNNYVALE, Calif. and NEWBURY, United Kingdom, July 20, 2018 (GLOBE NEWSWIRE) -- eGain (NASDAQ:EGAN), the leading provider of cloud-based customer engagement solutions, today announced its integration with Apple Business Chat. According to Gartner, requests for customer support through consumer mobile messaging apps will exceed requests for customer support through traditional social media by 2019*. Moreover, 56% of consumers surveyed in a Nielsen study would rather message a business than call customer service, and 67% expect to message businesses even more over the next two years. Key capabilities Among key capabilities of the integrated solution are: Enabling hundreds of millions of consumers on iPhone and iPad to interact with businesses through the Messages app Leverage eGain AI to infer customer intent, power bot conversations through messaging, route escalations to contact center agents, and guide agents through messaging conversations Provide immersive customer experiences with
I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.Besök vårt pressrum